Clinician vs Patient Reporting of Baseline and Postbaseline Symptoms for Adverse Event Assessment in Cancer Clinical Trials
      QxMD      Google Scholar   
Citation:
JAMA Oncol vol 6 (3) 437-9
Year:
2020
Type:
Manuscript
Funding:
NCTN
Endpoint:
Secondary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
ppub
Note:
Alliance studies involved within the NCCTG N0591 meta-analysis: 982452, MC05C6, MC06C8, N00C1, N01C5, N01C8, N01C9, N0222, N03C5, N03CA, N05C7, N06C4, N07C1, RC0639, 959255, 971151, 979202, MC99C2, N0021, N0087, N00C9, N014C, N0242, N9942, and N9946.
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
9
Parents:
2288  
Children:
None
Program:
CCP
Primary Committee:
Health Outcomes
Sec. Committees:
   
Pharmas:
 
Grants:
U10CA180821, U10CA180882, UG1CA189823, U10CA180790, U10CA180838, P30CA008748  
Corr. Author:
 
Authors:
               
Networks:
LAPS-MN026, LAPS-NC007, LAPS-NY016   
Study
NCCTG-N0591
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
N/A
Keywords: